{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:11:40Z","timestamp":1777417900993,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To determine whether a specific dose of aspirin can be recommended for prevention of cardiovascular disease in patients with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCE<\/jats:title>\n                    <jats:p>Biomedical literature was accessed through MEDLINE (1990\u2013February 2002). Key terms included diabetes, cardiovascular protection, and aspirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>Pharmacologic and clinical studies focusing on the dose\u2013response relationship of aspirin therapy were reviewed. Evidence supports the benefit of low-dose aspirin therapy in reducing vascular events in secondary and primary prevention trials in various patient populations; however, some studies suggest larger doses of aspirin may be needed in certain patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Review of the evidence does not support a particular dose of aspirin for cardiovascular protection in diabetic patients. Clinical guidelines recommend aspirin therapy in the range of 81\u2013325 mg\/d. However, due to an increased prevalence of cardiovascular morbidity and disturbances in coagulation in diabetic patients, the dose of aspirin for prevention of cardiovascular disease in these individuals may be different from that in other populations and requires further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1c101","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:28:03Z","timestamp":1054744083000},"page":"116-121","source":"Crossref","is-referenced-by-count":6,"title":["Aspirin Dose for Prevention of Cardiovascular Disease in Diabetics"],"prefix":"10.1177","volume":"37","author":[{"given":"Sandra N","family":"Nowak","sequence":"first","affiliation":[{"name":"Sandra N Nowak PharmD, Postdoctoral Research Fellow, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda A","family":"Jaber","sequence":"additional","affiliation":[{"name":"Linda A Jaber PharmD, Associate Professor, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,1,1]]},"reference":[{"key":"bibr1-aph.1C101","first-page":"1","volume":"13","author":"UK Prospective Diabetes Study 6","year":"1990","journal-title":"Diabetes Res"},{"key":"bibr2-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390404"},{"key":"bibr3-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6921.81"},{"key":"bibr4-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70225-5"},{"key":"bibr5-aph.1C101","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1767"},{"key":"bibr6-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301808"},{"key":"bibr7-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006213222503"},{"key":"bibr8-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.8.2006.2006"},{"key":"bibr9-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642656"},{"key":"bibr10-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(98)00126-1"},{"issue":"1","key":"bibr11-aph.1C101","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.2337\/diacare.25.2007.S78","volume":"24","author":"The American Diabetes Association","year":"2002","journal-title":"Diabetes Care"},{"key":"bibr12-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2423"},{"key":"bibr13-aph.1C101","first-page":"231","volume":"11","author":"Undas A","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"bibr14-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.85.3.1077"},{"key":"bibr15-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615701"},{"key":"bibr16-aph.1C101","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.8.1476"},{"key":"bibr17-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"bibr18-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490100090033"},{"key":"bibr19-aph.1C101","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-2-200201150-00016"},{"key":"bibr20-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6618.313"},{"key":"bibr21-aph.1C101","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Final report on the aspirin component of the ongoing Physicians' Health Study","year":"1989","journal-title":"N Engl J Med"},{"key":"bibr22-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11475-1"},{"key":"bibr23-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"bibr24-aph.1C101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03539-X"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1C101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:04Z","timestamp":1777374364000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1C101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1345\/aph.1C101"],"URL":"https:\/\/doi.org\/10.1345\/aph.1c101","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}